This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rite Aid Reports Same Store Sales For November

Rite Aid Corporation (NYSE: RAD) today announced sales results for November.

Monthly Sales

For the five weeks ended Nov. 30, 2013, same store sales increased 2.8 percent over the prior-year period. November front-end same store sales increased 0.4 percent. Pharmacy same store sales, which included an approximate 81 basis points negative impact from new generic introductions, increased 3.9 percent. Prescription count at comparable stores increased 0.1 percent over the prior-year period.

Total drugstore sales for the five-week period increased 1.6 percent to $2.434 billion compared to $2.396 billion for the same period last year. Prescription sales accounted for 68.1 percent of drugstore sales, and third party prescription sales represented 97.1 percent of pharmacy sales.

Superstorm Sandy Impact

The Company estimates that the cycling of the impact of Superstorm Sandy on prior year results had a positive impact of 0.4 percent on front end same store sales and 1.6 percent on comparable store prescription count growth.

Quarterly Sales

Same store sales for the 13-week period ended Nov. 30, 2013 increased 2.3 percent over the prior-year period. Front-end same store sales decreased 0.2 percent while pharmacy same store sales increased 3.5 percent. Prescription count at comparable stores increased 0.7 percent over the prior-year period.

Total drugstore sales for the 13 weeks ended Nov. 30, 2013 increased 1.9 percent with sales of $6.330 billion compared to $6.213 billion for the same period last year. Prescription sales represented 68.6 percent of total drugstore sales, and third party prescription sales represented 97.1 percent of pharmacy sales.

Year-to-Date

Same store sales for the 39-week period ended Nov. 30, 2013 increased 0.3 percent over the prior-year period. Front-end same store sales were flat compared to the prior-year period while pharmacy same store sales increased 0.4 percent. Prescription count at comparable stores increased 0.2 percent over the prior-year period.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,638.35 -91.76 -0.52%
S&P 500 2,064.57 -12.21 -0.59%
NASDAQ 4,978.1840 -31.03 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs